Drugs / CE-VST01-JC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05541549 | Feb 2023 → Mar 2024 | progressive multifocal leukoencephalopathy | Cellevolve Bio Inc | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CE-VST01-JC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05541549 ↗ |
| Modality | Cell therapy | “matched virus-specific T-cell product (CE VST01-JC)” NCT05541549 ↗ |
| Route | Intravenous | “administered as an intravenous (IV) infusion” NCT05541549 ↗ |